Replimune Group, Inc. $REPL Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 2.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,624,048 shares of the company’s stock after selling 48,722 shares during the period. Geode Capital Management LLC owned approximately 2.09% of Replimune Group worth $15,090,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in REPL. US Bancorp DE boosted its holdings in Replimune Group by 582.6% during the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after buying an additional 3,921 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Replimune Group by 99.9% during the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock valued at $92,000 after acquiring an additional 4,925 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Replimune Group by 106.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock worth $111,000 after acquiring an additional 5,876 shares in the last quarter. Optimize Financial Inc purchased a new stake in shares of Replimune Group during the 1st quarter worth approximately $140,000. Finally, Corebridge Financial Inc. grew its holdings in shares of Replimune Group by 11.0% in the 1st quarter. Corebridge Financial Inc. now owns 33,584 shares of the company’s stock worth $327,000 after acquiring an additional 3,317 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $47,392.80. Following the transaction, the insider owned 123,088 shares in the company, valued at approximately $1,120,100.80. This trade represents a 4.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Konstantinos Xynos sold 7,248 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $65,956.80. Following the sale, the insider owned 139,685 shares of the company’s stock, valued at $1,271,133.50. The trade was a 4.93% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 5.20% of the company’s stock.

Replimune Group Trading Down 2.9%

Replimune Group stock opened at $9.71 on Tuesday. The stock has a 50-day moving average price of $7.38 and a 200 day moving average price of $7.50. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $14.80. The stock has a market cap of $761.65 million, a PE ratio of -2.81 and a beta of 0.66. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REPL. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price on the stock in a research report on Monday, October 20th. Leerink Partnrs upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Monday, October 27th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $4.00 to $18.00 in a research report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Replimune Group in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Replimune Group currently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.